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Thrombocytopenia in Neonates
Bernhard Resch
Abstract
Thrombocytopenia defined as platelet count below 150,000/μL is not an uncom-
mon event at the neonatal intensive care unit (NICU). In our region we calculated a 
prevalence of nearly 2 of 1000 live births. Early-onset neonatal thrombocytopenia 
(NT) occurring within the first 72 hours of life is more common than late-onset 
NT. Preterm infants are affected more often than term infants and bacterial infec-
tion is the most common diagnosis associated with NT. There are a lot of maternal, 
perinatal, and neonatal causes associated with NT and complications include 
bleedings with potentially life-threatening intracranial hemorrhage. Alloimmune 
thrombocytopenia (NAIT) often presents with severe thrombocytopenia (<30,000/
μL) in otherwise healthy newborns and needs careful evaluation regarding HPA-1a 
antigen status and HLA typing. Platelet transfusions are needed in severe NT and 
threshold platelet counts might be at ≤25,000/μL irrespective of bleeding or not. 
Immune mediated NT recovers within 2 weeks with a good prognosis when there 
happened no intracranial hemorrhage. This short review gives an overview on etiol-
ogy and causes of NT and recommendations regarding platelet transfusions.
Keywords: neonatal thrombocytopenia, prematurity, platelet transfusion, 
alloimmune thrombocytopenia, early- and late-onset thrombocytopenia, severity, 
intracranial hemorrhage, bleeding, incidence, mortality
1. Introduction
Thrombocytopenia, defined as a platelet count <150,000/μL or below 
150 × 109/L, occurs more often during the neonatal period than in any other 
populations. Thrombocytopenia implicates an increased risk of bleeding, and 
is associated with significant morbidity mainly due to intracranial hemor-
rhage. As a result, it is important to identify infants at risk, and if indicated (see 
below recommendations for platelet transfusion), to initiate therapy to prevent 
complications.
Recently our research group on neonatal infectious diseases and epidemiology 
at the Medical University of Graz, Austria, published retrospectively collected 
data on neonatal thrombocytopenia (NT) [1]. Of 371 neonates diagnosed as 
having NT, 312 (84.1%) had early-onset NT (EOT) and 59 (15.9%) had late-onset 
NT (LOT) defined as NT before or after 72 hours of age, respectively. The degree 
of NT was defined as mild, platelet counts of 100,000–150,000/μL; moderate, 
counts of 50,000–<100,000/μL; severe, counts of 30,000–<50,000/μL; and very 
severe, counts of <30,000/μL, according to the description of Wiedmeier et al. [2]. 
The majority—nearly three-fourth of the cohort—had mild (33%) to moderate 
(38%) NT; only 14% had severe and 15% very severe NT [1]. Seventy-six percent 
of the neonates were born preterm and this rate was approximately the same for 
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either EOT or LOT (76 and 77%, respectively). The percentage of extremely low 
gestational age newborns (ELGAN, below 28 weeks of gestational age) was 20% in 
total. The incidence of NT in preterm infants was 4% (282/6964) in our population 
during the years 1990–2012. Thus, we calculated the prevalence of NT as being 
1.8/1000 live births in our region (Southern Styria with around 200,000 live births 
during the study period) [1].
A total of 40 neonates (10.8%) died; 36 (90%) had EOT, and 4 (10%) had 
LOT; and 30 (75%) neonates were still thrombocytopenic at the time of death. 
Interestingly, bleeding signs were significantly associated with mortality in our study. 
On the other hand, severity of NT was not associated with mortality. Only cutane-
ous bleedings were found to be associated with severity of NT. The mean duration 
of NT was significantly longer in case of LOT compared to EOT (8.9 vs. 16.8 days; 
p < 0.001); and the duration was positively correlated with severity of NT. At least we 
found that platelet transfusion did not shorten the duration of NT [1].
2. Etiology and causes of neonatal thrombocytopenia
Thrombocytopenia is present in 1–5% of newborns at birth, and severe throm-
bocytopenia defined as platelet count below 50,000/μL occurs in 0.1–0.5% [3]. 
But thrombocytopenia is more common in neonates needing intensive care at the 
neonatal intensive care unit (NICU) with rates up to 50%. Every fifth newborn is at 
risk at the NICU to develop thrombocytopenia, and 8% of preterm and 6% of term 
infants are at risk for severe thrombocytopenia [4].
Main mechanisms of thrombocytopenia include increased platelet consumption 
and/or sequestration, and often neonatal thrombocytopenia is of multifactorial 
origin. Thus, on the one hand there is rapid consumption like in case of necrotiz-
ing enterocolitis (NEC) and on the other hand slow recovery by impaired platelet 
production.
There are a lot of maternal, perinatal, and neonatal causes that might be associ-
ated with the occurrence of NT. Figure 1 shows the main features and causes of NT 
by separating early- and late-onset thrombocytopenia [5].
Figure 1. 
Etiology and causes of early- and late-onset thrombocytopenia.
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Own data on neonatal diagnoses associated with thrombocytopenia retrospec-
tively collected over 23 years compared to data from Tunisia and Turkey—in order 
to give a broader view on dominant causes and diagnoses—are shown in Table 1 [1]. 
Main diagnoses were early- and late-onset sepsis, and intrauterine growth restric-
tion. Other dominant features like asphyxia and NEC differed between centers as 
did more sporadic causes of NT.
An association of NT with bacterial infection is well known. Rates have been 
reported of 30% [7], 36% [8], and 47% [1]. And severe NT and very severe NT 
were commonly associated with sepsis [1, 8]. Late-onset NT often is reported to 
result in prolonged courses of NT [1, 9, 10].
Birth asphyxia is a common diagnosis associated with NT and reported up to 
25% [1, 7, 8]. NEC is a morbidity often complicated by NT. Resch et al. reported a 
rate of 4.1% [1] and that was twice as high as reported elsewhere [7, 8]. Other asso-
ciations, including chromosomal anomalies, metabolic disorders, and thromboses, 
Austria [1] 2018 Tunisia [] 2016 Turkey [] 2013
371 cases 23-year 
period
112 episodes 4-year 
period
134 cases 5-year 
period
EOS 128 (34) LOS 29 (19) Sepsis 45 (34)
Asphyxia 95 (25) IUGR 26 (17) IUGR 25 (19)
LOS 47 (13) EOS 23 (15) Preeclampsia 13 (9.7)
NEC 16 (4.1) DIC 22 (14) Maternal thr. 6 (4.5)
Chrom. 
aberration
15 (3.9) PIH 18 (12) Drug 5 (3.7)
HDN 9 (2.4) Unexplained 15 (9.6) Hydrops fetalis 4 (3.0)
CMV 9 (2.4) Cong. rubella 6 (3.8) Perinatal asphyxia 4 (3.0)
MPD 6 (1.6) Asphyxia 5 (3.2) Ablatio placenta 4 (3.0)
NAIT 4 (1.0) NEC 3 (1.9) Drug + sepsis 4 (3.0)
K-M-syndrome 2 (0.5) Tris 21 2 (1.3) Rh incompatibility 4 (3.0)
Metab. 
disorders
2 (0.5) CMV 2 (1.3) NEC 3 (2.2)
Thrombosis 2 (0.5) Exchange transf. 2 (1.3) Maternal ITP 3 (2.2)
Toxoplasmosis 1 (0.7) Congenital anomaly 2 (1.5)
Neonatal lupus 1 (0.7) Tris 21 2 (1.5)
Maternal ITP 1 (0.7) NAIT 2 (1.5)
HELLP syndrome 2 (1.5)
Metab. disorders 2 (1.5)
Maternal GDM 2 (1.5)
Neonatal jaundice 1 (0.8)
Mother with SLE 1 (0.8)
Data are given as number (%).
EOS: early-onset sepsis, LOS: late-onset sepsis, NEC: necrotizing enterocolitis, HDN: hemolytic disease of the 
newborn, CMV: cytomegalovirus, MPD: myeloproliferative disease, NAIT: neonatal alloimmune thrombocytopenia, 
K-M-syndrome: Kasabach-Merritt syndrome, DIC: disseminated intravasal coagulation, IUGR: intrauterine growth 
restriction, GDM: gestational diabetes mellitus, SLE: systemic lupus erythematodes.
Table 1. 
Neonatal diagnoses associated with thrombocytopenia from three studies (Austria [1], Tunisia [6], and  
Turkey [7]).
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ranged between 0.5 and 3.9% in the literature [1, 6–8]. Von Lindern et al. [8] 
reported on a 10% rate of hemolytic disease of the newborn (HDN), which was four 
times higher compared to the rate of 2.4% reported by Resch et al. [1].
In preterm infants, NT is rarely diagnosed at low rates between 4 and 12%  
[1, 10]. Most studies report higher rates of NT ranging between 22 and 35% [2, 
3, 8, 11–13], and highest rates (53–70%) have been reported from developing 
countries [14, 15]. Own data revealed that 75% of a cohort of thrombocytopenic 
neonates were preterm neonates. The association between NT and prematurity or 
low birth weight is well documented [3, 6–8, 11, 16, 17]. In this context small-for-
gestational age (SGA) is a well-known risk factor for developing NT [11, 16, 17], 
and rates have been reported as high as 30–53% [1, 17, 18].
3. Pathomechanisms of neonatal thrombocytopenia
3.1 Immune-mediated thrombocytopenia
One possibility of low platelet counts is increased destruction that is observed in 
several neonatal conditions. Placental crossing of maternal antibodies is the cause 
of NT in case of immune-mediated NT, which destroys neonatal platelets. Immune-
mediated processes are very common causes of neonatal thrombocytopenia, and 
the antibodies responsible may be autoantibodies, drug-dependent antibodies, or 
alloantibodies. The mechanism behind is an interaction with platelet membrane 
antigens or the formation of immune complexes, which can bind to reticuloendo-
thelial cell Fc receptors. As a result platelets become cleared from blood vessels [19].
3.1.1 Neonatal alloimmune thrombocytopenia (NAIT)
In NAIT, fetal platelets contain an antigen inherited from the father that the 
mother lacks. The mother produces antiplatelet antibodies from the immunoglobu-
lin G (IgG)-type against the platelet antigen during pregnancy that is recognized 
as being foreign. Thereafter IgG antibodies cross the placenta and destroy fetal 
platelets that express the paternal antigen [20].
3.1.2 Neonatal autoimmune thrombocytopenia
It is mediated by maternal autoantibodies that react with both maternal and 
fetal platelets. This occurs in maternal autoimmune disorders, including immune 
thrombocytopenia purpura (ITP) and systemic lupus erythematosus (SLE) [20].
3.1.3 Drug-induced immune thrombocytopenia
Drug-induced immune thrombocytopenia is typically caused by platelet destruc-
tion from maternal drug-dependent antibodies and, rarely, by neonatal antibodies. 
Bone marrow suppression also can result in thrombocytopenia due to decreased plate-
let production. Neonatal drug-induced immune thrombocytopenia is usually caused 
by maternal drug-dependent antibodies formed after drug exposure to the mother 
during pregnancy [19, 20]. Maternal antibodies can cross the placenta and affect 
fetal and neonatal platelets. This mechanism is similar to that seen in mothers with 
primary immune thrombocytopenia purpura (ITP). Drugs associated with maternal 
drug-mediated platelet destruction include quinine, quinidine, trimethoprim-sulfa-
methoxazole, vancomycin, penicillin, rifampin, carbamazepine, phenytoin, valproic 
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acid, ceftriaxone, ibuprofen, mirtazapine, oxaliplatin, suramin, GP IIb/IIIa inhibitors 
(e.g., abciximab, tirofiban, eptifibatide), and heparin. Some drugs may cause throm-
bocytopenia at the initial exposure without prior sensitization. This commonly occurs 
with the glycoprotein IIb/IIIa inhibitors and has also been seen with other drugs, such 
as vancomycin and piperacillin [21]. Rarely, platelet destruction can be caused by 
neonatal drug-dependent antibodies, such as seen in heparin-induced thrombocyto-
penia (HIT). HIT antibodies can promote thrombosis by inducing platelet activation. 
Patients with suspected HIT require immediate institution of a non-heparin antico-
agulant [20].
3.1.4 Non-immune drug-induced NT
Many drugs used as chemotherapy cause thrombocytopenia by bone marrow 
suppression (non-immune drug induced NT). Antibiotics, such as linezolid, daptom-
ycin, and valacyclovir can also cause moderate thrombocytopenia in some patients 
by suppression of platelet production [20].
3.2 Thrombopoiesis
Platelet production—thrombopoiesis—is initiated by a thrombopoietic stimulus, 
and the most important stimulant is the chemokine thrombopoietin (TPO) besides 
several cytokines and chemokines that are also involved in the process (e.g., IL-3, 
IL-6, IL-11, GM-CSF, stromal cell-derived factor-1 and fibroblast growth factor 4) 
[22]. TPO promotes the proliferation of megakaryocyte progenitors and the matura-
tion of megakaryocytes. These mature megakaryocytes are at least responsible for 
generation and release of new platelets into the blood vessels [22].
3.2.1 The homeostasis of TPO levels
The homeostasis of TPO levels is regulated by the thrombopoietin c-Mpl 
(myeloproliferative leukemia protein) receptor-mediated uptake and destruction 
of the hormone with the aim to have steady-state amounts of hepatic TPO. When 
bound to the platelet c-Mpl receptors, the hormone gets removed from the cir-
culation and blood levels are reduced. In case of inflammatory processes IL-6 is 
released from macrophages and fibroblasts (via TNF-α) and enhances hepatic TPO 
production [22].
Another phenomenon adding to the steady-state model of TPO regulation is 
the physiological response to severe thrombocytopenia of bone marrow stromal 
cells, which under normal circumstances produce low amounts of TPO-mRNA but 
increase transcription markedly in case of thrombocytopenia [22]. IL-6, stimulated 
by inflammation processes, leads to increased levels of TPO resulting in reactive 
thrombocytosis; and TPO is now confirmed as the final mediator of inflammation-
induced thrombocytosis [22].
There are similarities and differences between neonatal and adult thrombocy-
topenia. Plasma TPO concentrations are known to be higher in healthy neonates 
compared to healthy adults. But in NT TPO levels are lower even when adult throm-
bocytopenia has the same degree [19]. Interestingly, megakaryocyte progenitors of 
neonates have a higher proliferative potential than those of adults resulting in larger 
megakaryocytes. Neonatal megakaryocyte progenitors are more sensitive to TPO 
both in vitro and in vivo than adult progenitors [19]. Cells are present both in the 
bone marrow and the peripheral blood of neonates in contrast to adult ones that are 
almost exclusively present in the bone marrow [19] (Figure 2).
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3.2.2 Clinical conditions and their pathomechanisms
Chronic intrauterine hypoxia is commonly observed when associated with placen-
tal insufficiency due to all conditions of pregnancy-induced hypertension (hyper-
tension alone or pre-eclampsia or hypertension-elevated liver enzymes-low platelet 
counts—HELLP—syndrome, and gestational or maternal diabetes) and is usually 
manifested by fetal intrauterine growth restriction and hematological abnormalities 
including NT. The pathomechanisms behind are not completely understood but 
lower levels of megakaryocyte progenitors have been found that increased during 
normalization of NT [23].
The hematopoietic microenvironment plays a significant role in chronic 
hypoxia-induced suppression of megakaryocytopoiesis, and, not astonishingly, 
preterm infants’ megakaryocyte progenitors are more vulnerable to ischemic insults 
than progenitors from term neonates or adults [24].
Overall, observations demonstrated that thrombopoiesis is up-regulated in 
neonatal sepsis and/or NEC, but this effect can also be down-regulated resulting in 
“hypoproliferation” [19]. Platelet factor 4 is a potent inhibitor of megakaryocyte 
proliferation that is released from activated platelets during severe sepsis. This 
regulates neonatal megakaryocytopoiesis negatively [25].
In HIV-associated thrombocytopenia, evidence that splenic platelet sequestration 
decreased platelet production had been observed despite larger megakaryocyte 
mass [26]. In neonates, ineffective platelet production was described as being the 
main mechanism of HIV-associated thrombocytopenia [27]. The mechanisms in 
other congenital infections of the TORCH complex mostly remain to be speculative 
despite their common association with NT [20].
4. Neonatal alloimmune thrombocytopenia (NAIT)
Harrington et al. first described in 1953 two infants born with severe thrombo-
cytopenia to mothers with normal platelet counts [28]. Both newborns recovered 
despite severe bleeding and other complications after 2 and 8 weeks, respectively. 
Figure 2. 
A simplified model of TPO regulation.
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This immunological disease now is well described as neonatal alloimmune throm-
bocytopenia (NAIT).
In 1962 a maternal antibody against a platelet alloantigen was detected causing 
NAIT [29]. This platelet alloantigen determined as PlA1 was the cause of platelet 
destruction in two of the newborns reported in the study by Shulman et al. [29]. 
Later, PlA1 was found to be identical to an antigen called Zwa [30] and now is known 
as human platelet antigen 1a (HPA-1a). Over the following years several other plate-
let-specific antigens were detected as being able to induce maternal immunization 
during pregnancy with subsequent fetal platelet destruction, thus, being an impor-
tant complication of pregnancy with diagnostic and therapeutic challenges [31].
The incidence of NAIT calculated from large studies on women negative for 
HPA-1a lies in between 1 in 1000–2000 HPA-1a positive newborns [32–34]. The 
incidence of HPA-1a negative phenotype is about 2.5%; and one-third is at high risk 
to get immunized in case of a HPA-1a positive fetus, and this association is triggered 
by HLA-DR antigen B3*0101 positivity [31].
The main problem of NAIT is that it can lead to serious bleedings including 
intracranial hemorrhage and death. In full term infants it is the leading cause of 
intracranial hemorrhage [35]. Other clinical findings are petechiae or purpura 
associated with very low platelet counts without any explanation (after exclusion 
of bacterial and viral infection—TORCH complex, or disseminated intravascular 
coagulation). A previous history of NAIT results in more severe disease. Around 
10–20% of the newborns have intracranial hemorrhages, and the vast majority of 
80% occurs already before birth. After birth the greatest risk of bleeding is in the 
time span of the first 4 days of life. Untreated, NT resolves within 2–3 weeks [35].
Even in mildly affected infants serological investigation including ABO, HPA 
and HLA typing (further details are beyond the scope of this chapter) is indicated 
because results can be critical for effective management of future pregnancies. For 
the most informative evaluation, it is important to study blood samples from both 
mother and father.
A systematic review on incidence and consequences of NAIT reported on 6 of 21 
studies (full text analysis) from initial 768 studies [36]. Nearly 60,000 newborns 
were screened, with severe thrombocytopenia in 89 cases (0.15%); and NAIT was 
diagnosed in 24 of these 89 newborns (27%) resulting in an incidence of 1:2500. Six 
newborns (25%) had diagnosis of intracranial hemorrhage and most likely of ante-
natal origin. Hence, intracranial hemorrhage due to NAIT occurred in 1:10–11,000 
newborns [36, 37]. This is the most severe complication having a 1–7% risk of 
death. Survivors are known to have sequelae including mental retardation, cerebral 
palsy, cortical blindness and seizures in 7–26% of pregnancies [38]. In contrast to 
ABO- or Rh-incompatibility, immunization occurs often during the first pregnancy.
Severity of NAIT is associated with parity (second pregnancy often more 
severe), HPA-a1 antibodies level, outcome of a former pregnancy, and the type of 
alloimmunization (HPA-1a more severe than HPA-5b) and the HLA type: homo-
zygote HPA-1b and negative for HLA DRB3*0101 leads to no NAIT with negative 
predictive value of 99.6%, but homozygote HPA-1b plus HLA DRB3*0101 positivity 
leads to NAIT with a positive predictive value of 35% [39] Interestingly, antenatal 
IVIG is again more effective depending on HLA status [31]. Also of importance is 
the risk of recurrent intracranial hemorrhage of being 80–90%.
4.1 How to proceed in case of suspected NAIT?
At first the medical history should be looked for a previous neonate with throm-
bocytopenia of unknown origin and/or having platelet count below 50 × 109/L and/or 
previous history of intracranial hemorrhage of uncertain origin [40]. Is the mother 
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thrombocytopenic, one should evaluate for maternal anti-platelet auto-antibodies 
or a history of immune thrombocytopenia. Is the mother not thrombocytopenic, 
maternal and paternal platelet antigen typing and maternal platelet HPA antibody 
testing should be done. In case of incompatibility at HPA loci (1–6, 9, 15) and pres-
ence of specific maternal HPA-antibody, diagnosis of NAIT is given. Are there no 
incompatibilities and no anti-platelet antibodies or only nonspecific antibodies of the 
mother present, then no further evaluation is necessary besides maternal antibodies 
against paternal platelets are positive (preferred at 30 weeks’ gestation). A third vari-
ant is a positive incompatibility without maternal anti-HPA antibodies (provided no 
reaction with paternal platelets), then there is no further evaluation necessary [40].
During pregnancy, strategies using IVIG and corticosteroids have been success-
ful. The success rate with IVIG alone was reported to be as high as 98.7% and is in 
line with a Cochrane analysis reporting 97.3% [37, 41]
5. Complications of neonatal thrombocytopenia
5.1 Bleedings
The prevalence of hemorrhages in thrombocytopenic neonates is approximately 
20–30% according to the literature [16, 42]. The risk of hemorrhage is associated 
with lower gestational age, definite causes of thrombocytopenia, and the severity of 
concomitant morbidities [8, 9, 43].
An observational study including 169 neonates with severe NT identified severe 
sepsis and NEC as the most common diagnoses associated with bleeding neonates 
[35]. In those neonates with mild or no hemorrhage, the most common cause of 
severe NT has been documented as being intrauterine growth restriction and mater-
nal pregnancy-induced hypertension [44].
A causal link between thrombocytopenia and intracranial hemorrhage is not 
known. Interestingly, platelet transfusions could not reduce the risk of intracranial 
bleedings [1, 45]. The majority of preterm neonates with severe intraventricular 
hemorrhage (IVH) becomes thrombocytopenic during the course of bleeding, thus, 
thrombocytopenia might not be the cause of IVH [46, 47]. Additionally, consider-
ing IVH as a multifactorial event, it seems highly unlikely that an isolated low 
platelet count leads to bleeding [44].
Another point of interest is the fact that comparable rates of IVH have been 
reported independent of the severity of NT [17]. In contrast, cutaneous bleeding 
conditions have been associated with the severity of NT [1, 46], and the prevalence 
of skin bleeding in thrombocytopenic neonates has been reported as being as high 
as 81% [48].
5.2 Mortality
The association of increased mortality rates with increasing numbers of platelet 
tranfusions mainly reflects the severity of the underlying disease or condition, 
for example, extremely low gestational age newborn. These infants are known 
to be at high risk for severe IVH that again is associated with high risk of death. 
Additionally, the more severe NT is the higher is the rate of mortality, and some 
data suggest that NT contributes to mortality rather than simply being a measure 
of disease severity [5]. Three studies from the USA, the UK, and Mexico reported 
higher mortality rates in neonates who had received platelet transfusions compared 
with those who had not [49–51]. The direct effects of platelet transfusions are ques-
tionable, as specific effects have not been properly evaluated, and the influence of 
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preexisting morbidity is difficult to evaluate [44]. But as shown by Curley et al. 
[52] (see below), waiting until platelets have fallen below 25 × 109/L before indicat-
ing transfusion is of more benefit than earlier transfusion at cut-off level below 
50 × 109/L. Again the observation of Kenton et al. [53] is of interest who did not 
find an improvement in NEC-associated mortality with an increasing number or 
volume of platelet transfusions.
6. Recommendations for treatment with platelet transfusions
Platelet transfusions are commonly used in preterm infants with NT at different 
threshold values. In 2018, a milestone study prospectively investigated whether 
platelet transfusion should be given at platelet-count thresholds of 50,000/μL 
(high-threshold group) or 25,000/μL (low-threshold group) [52]. In this multi-
center trial, preterm infants born at less than 34 weeks of gestation in whom severe 
thrombocytopenia was diagnosed were included and randomly assigned to high 
or low platelet transfusion groups. The primary outcome was death or new major 
bleeding within 28 days after randomization. Of 660 infants (median birth weight, 
740 g; and median gestational age, 26.6 weeks), 90% of the infants (296 of 328 
infants) of the high-threshold group received at least one platelet transfusion, as 
compared with 53% (177 of 331 infants) in the low-threshold group. A new major 
bleeding episode or death happened in 26% of the infants in the high-threshold 
group and in 19% in the low-threshold group (odds ratio, 1.57; 95% confidence 
interval 1.06–2.32; p = 0.02). Most exciting, there was no significant difference 
between corresponding rates of serious adverse events (25 vs. 22%) [51].
An overview of recommendations at different thresholds of thrombocyte counts 
is given in Table 2.
Cut-off value 
thrombocyte 
counts
Recommendation Authors
<20 × 109/L All neonates (prophylactic) Blanchette et al. [54, 55]; Gibson et al. [56]; 
Chakravorty et al. [57]; Carr et al. [58]
20–29 × 109/L Non-bleeding term and preterm 
infant
Blanchette et al. [55]; Roberts et al. [59]; 
Calhoun et al. [60]; Sola-Visner et al. [61]; 
Murray [62]; Gibson et al. [56]; Carr et al. 
[58]; Sparger et al. [63]
Bleeding neonates Murray et al. [62]; Roberts et al. [4, 44]; 
Chakravorty et al. [57]
30–49 × 109/L Preterm infants (unstable neonate, 
first week of life, surgery or invasive 
procedures)
Blanchette et al. [54, 55]; Roberts et al. [59]; 
Sola-Visner et al. [61]; Calhoun et al. [60]; 
Murray [62]; Roberts et al. [4]; Sparger et al. 
[63]
Bleeding neonates Blanchette et al. [54]; Roberts et al. [44, 59]; 
Gibson et al. [56]; Chakravorty et al. [57]
50–99 × 109/L Non-bleeding sick preterm Blanchette et al. [54, 55]; Roberts et al. [59]
Bleeding neonates Roberts et al. [4, 44, 59]; Murray et al. [62]; 
Sola-Visner et al. [61]; Sparger et al. [63]
100–150 × 109/L No recommendations —
Table 2. 
Recommendations for platelet transfusions depending on different thrombocyte counts.
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7. Conclusions
In conclusion, neonatal thrombocytopenia is a common problem at the neonatal 
intensive care unit. In most cases, it is a mild to moderate, self-limited entity. In 
severe cases, immune-mediated disease has to be suspected warranting prompt diag-
nosis and careful management. The threshold for platelet transfusions better should 
be at thrombocyte counts of 25–30,000/µL due to recent data reporting on a reduced 
mortality rate using a more restrictive transfusion regimen.
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